Keyphrases
Colorectal Cancer
100%
Metastatic Colorectal Cancer (mCRC)
100%
Molecular Targeted Therapy
100%
BRAF mutant
100%
BRAF Inhibitor (BRAFi)
100%
Second-line Treatment
66%
Monotherapy
66%
Anti-EGFR
66%
Poor Prognosis
66%
Bevacizumab
66%
Irinotecan
66%
Melanoma
33%
Therapeutic Targeting
33%
Chemotherapy
33%
Molecular Characterization
33%
Randomized Trial
33%
5-fluorouracil (5-FU)
33%
Epidermal Growth Factor Receptor
33%
Epidermal Growth Factor Receptor Signaling
33%
BRAF mutation
33%
Cetuximab
33%
BRAF V600E mutation
33%
First-line Chemotherapy
33%
Vemurafenib
33%
Oxaliplatin
33%
Feedback Activation
33%
Chemotherapy Combinations
33%
MEK Inhibitor (MEKi)
33%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Cancer
100%
Epidermal Growth Factor Receptor
100%
Metastatic Colorectal Cancer
75%
Chemotherapy
50%
Bevacizumab
50%
Irinotecan
50%
Monotherapy
50%
First-Line Chemotherapy
25%
Melanoma
25%
Mitogen Activated Protein Kinase Kinase Inhibitor
25%
Vemurafenib
25%
Oxaliplatin
25%
Cetuximab
25%
Fluorouracil
25%